Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

But the popular injection is seeing new competition with Mounjaro, and now a daily pill which could help patients lose 16 ...

The company's shares are down roughly 34 percent so far this year following major supply line disruptions pushing physicians to prescribe Eli Lilly's tirzepatide-based injection drugs Zepbound and ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Ozempic is also approved to help: Ozempic contains the active ingredient semaglutide. This article discusses where to inject Ozempic and other information about injection sites. To learn more ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

while the one-two he played from a sideline ball to draw Clare level was as good as any of the wonder points he scored against the same opposition last July. 8 DAVID REIDY: Brilliantly read the ...

In the diabetes space, there have been a number of breakthroughs that the industry can highlight, such as the approval of Novo Nordisk’s Ozempic (semaglutide injection) and Eli Lilly’s ...